Skip to content
Acceleron Pharma

Investors/Media

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Oct 5, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that it has issued 810,810 shares of common stock at the public offering price of $37.00 ...
Sep 20, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics intended to treat serious and rare hematologic, neuromuscular, and pulmonary diseases, today announced that it has priced an underwritten public ...
Sep 19, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare hematologic, neuromuscular, and pulmonary diseases, today announced that it intends to offer and sell, subject to ...
Sep 19, 2017
- Clinical development and research efforts focused on hematological, neuromuscular and pulmonary diseases - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat ...
Sep 19, 2017
- Acceleron gains rights to fund, develop, and lead global commercialization of sotatercept in pulmonary arterial hypertension - - Acceleron expects to initiate a Phase 2 trial of sotatercept in pulmonary arterial hypertension in 1H 2018 - - Preclinical results show potential first...
Sep 12, 2017
- Acceleron's senior management team and external experts to present clinical development programs and preclinical research efforts - - Live conference call and webcast scheduled for 8:00 a.m. EDT on September 19th - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Phar...
Sep 5, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, announced that The Lancet Oncology has published results from the Phase 2 ...
Aug 3, 2017
- Completed full enrollment of luspatercept MEDALIST and BELIEVE Phase 3 trials - - Presented updated luspatercept Phase 2 results in patients with MDS and beta-thalassemia receiving treatment for up to two years - - Treated first patient in ACE-083 Phase 2 study in Charco...
Aug 1, 2017
- Phase 2 trial in CMT expands wholly-owned ACE-083 program and muscle franchise into new area of high unmet medical need - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercial...
Jul 27, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN) today announced it will host a webcast and conference call on Thursday, August 3, 2017 at 5:00 p.m. EDT to discuss its second quarter 2017 financial results and provide an update on recent clinical development and corporate activities. ...
Jun 23, 2017
Results from ongoing study demonstrate increases in hemoglobin and decreases in red blood cell transfusion burden sustained for up to 24 months, with patients still active on treatment CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutica...
Jun 23, 2017
- Results from ongoing trials demonstrate increases in hemoglobin and reductions in red blood cell transfusion burden sustained for more than 26 months - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on th...
Jun 12, 2017
- DART Phase 2 study of dalantercept plus axitinib did not achieve its primary endpoint - - Acceleron to discontinue development of dalantercept - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focu...
Jun 1, 2017
- Companies expect to report top-line results from the Phase 3 studies in mid-2018 - SUMMIT, N.J. & CAMBRIDGE, Ma.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that they have completed target enrollment in the MEDALIS...
Jun 1, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that senior management will participate in two upcoming ...
Page:
...
Next Last
 
= add release to Briefcase